Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients

NCT00262314 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 509

Last updated 2013-11-14

Study results available
· View outcomes & findings →

Summary

The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Randy Bennett · EMD Serono

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2008-01-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262314 on ClinicalTrials.gov